KPV

A study was conducted on murine models to determine the peptide's potential on intestinal inflammation. The experiment was conducted on mice induced with bowel dysfunction, divided into two groups: one given the peptide and the other a placebo. After the study, researchers reported that the peptide mice exhibited reduced inflammatory cells and anti-enzymatic symptoms. Another study on a murine model of inflamed intestines involved the exposure of a chemical-induced compound of KPV combined with hyaluronic acid for targeted delivery.

One study was conducted on a cell culture of inflamed intestinal cells to determine the peptide's potential against inflammation. Inflamed intestinal cells were isolated and exposed to either the KPV peptide or a placebo. Upon exposure to the peptide, results indicated that even nanomolar concentrations of the peptide appeared to have led to anti-inflammatory results. The researchers suggested that the KPV peptide appeared to mainly act via PepT1 expression in these intestinal cells.

Wound healing is a complex biological process comprised of three general phases: inflammation, proliferation, and remodeling. Most cells possess a melanocortin 1 receptor (MC1R) receptor, where the a-MSH hormone binds, and researchers suggest that a-MSH hormone analogs such as KPV peptide may also bind to these receptors. One study explored the potential of KPV in enhancing corneal epithelial wound healing with a particular focus on the possible involvement of nitric oxide (NO).

A study was conducted to further understand the potential of KPV peptide in scar recovery in murine models. Half of the group of young mice were exposed to KPV and the other served as a control group. Half an hour after exposure, these mice underwent two surgical 6.5 mm wide incisions in their dorsal skin under anesthesia. The wound healing and scar formation were analyzed on days 3, 7, 40, and 60.